AKIN Criteria: Acute Kidney Injury After On-Pump Coronary Artery Bypass Graft (CABG)

NCT ID: NCT00780845

Last Updated: 2008-11-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

817 participants

Study Classification

OBSERVATIONAL

Study Start Date

2003-01-31

Study Completion Date

2008-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is evaluate clinical outcomes and 30-day mortality after on-pump CABG.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Eight hundred and seventeen patients was enrolled in this series and divided into to groups: Group AKI (-) - patients without acute kidney injury after on-pump CABG. Group AKI (+) - patients with acute kidney injury after on-pump CABG. AKI was defined as an absolute increase in serum creatinine (SCr) of more than or equal to 0.3 mg/dl (≥ 26.4 μmol/l) or a percentage increase in SCr of more than or equal to 50% (1.5-fold from baseline). The change in SCr concentration was defined as the difference between immediate postoperative concentration and the highest concentration during the stay in ICU. Clinical Outcomes and 30-day mortality was evaluate in this patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Failure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Acute Kidney failure Clinical outcomes On-pump Coronary artery bypass grafting Morbidity Mortality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AKI (-)

Patients without acute kidney injury after on-pump CABG

No interventions assigned to this group

AKI (+)

Patients with acute kidney injury after on-pump CABG

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients underwent on-pump coronary artery bypass grafting
* Patients with at least two serum creatinine values within 48 hours.

Exclusion Criteria

* Patients with end-stage kidney disease requiring renal replacement therapy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital de Base

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

São José do Rio Preto Medical School

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lilia N Maia, PhD

Role: STUDY_DIRECTOR

São José do Rio Preto Medical School

References

Explore related publications, articles, or registry entries linked to this study.

Machado MN, Miranda RC, Takakura IT, Palmegiani E, Santos CA, Oliveira MA, Mouco OM, Hernandes ME, Lemos MA, Maia LN. Acute kidney injury after on-pump coronary artery bypass graft surgery. Arq Bras Cardiol. 2009 Sep;93(3):247-52. doi: 10.1590/s0066-782x2009000900008. English, Portuguese, Spanish.

Reference Type DERIVED
PMID: 19851652 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CAAE-3438.0.000.140-08

Identifier Type: -

Identifier Source: org_study_id